Drug Profile
Research programme: anaemia therapeutics - CellNexus
Latest Information Update: 07 Sep 2021
Price :
$50
*
At a glance
- Originator CellNexus LLC
- Developer Takeda
- Class Cell therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Anaemia in USA
- 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
- 08 Jul 2009 Preclinical development is ongoing in the US